ePROs

  • 文章类型: Journal Article
    在接受全身治疗的癌症患者中使用智能手机应用程序可以促进早期发现症状和治疗副作用,并且可以得到机器学习(ML)的支持,以及时适应治疗并减少不良事件和计划外入院。
    我们旨在创建一个预警系统(EWS),以预测需要采取支持性干预措施以防止计划外访问的情况。为此,动态收集的标准化电子患者报告结果(ePRO)数据根据患者的个人旅程进行分析.关于福祉的信息,重要参数,药物,和自由文本也被考虑用于建立混合ML模型。我们的目标是整合ML在筛选大量数据方面的优势和人类专家的长期经验。鉴于高度不平衡的数据集的局限性(仅存在很少的不良事件)以及人类在监督此类事件的所有可能原因方面的局限性,我们假设应该可以将两者结合起来,以部分克服这些限制。
    通过采用白盒ML算法(即,规则学习者),从患者数据中学习规则(即,EPRO,重要参数,免费文本)是通过医疗设备智能手机应用程序捕获的。这些规则表明患者经历了计划外就诊的情况,因此,在EWS中捕获为警报触发器。每个规则都是根据成本矩阵进行评估的,其中假阴性(FN)的成本高于假阳性(FP,即,假警报)。然后根据成本对规则进行排名,并优先考虑最便宜的规则。最后,两名肿瘤专家对优先级较高的规则进行了审查,以进行合理性检查,并在附加条件下进行扩展.这种混合方法包括应用敏感的ML算法,产生几种潜在的不可靠的,但是完全由人类解释和修改的规则,然后可以由人类专家进行调整。
    从一组214名患者和超过16,000个可用数据条目中,机器学习的规则集在整个数据集上实现了19%的召回率和5%的准确率.我们将这种表现与人类专家定义的预测不良事件的一组条件进行了比较。这个“人类基线”没有发现我们数据集中记录的任何不良事件,即,它的召回率和准确率为0%。尽管我们的机器学习方法预计会有更多的结果,所涉及的医学专家a)理解并能够理解规则,b)认为有能力建议修改规则,其中一些可能会提高它们的精确度。建议的规则修改包括,例如,增加或收紧某些条件,使它们不那么敏感或改变规则的后果:有时进一步监测情况,应用某些测试(如CRP测试)或应用一些简单的疼痛缓解措施被认为是足够的,没有必要与医生进行昂贵的咨询。因此,我们可以得出结论,将机器学习作为一种鼓舞人心的工具,可以帮助人类专家为EWS制定规则。虽然人类似乎缺乏在没有这种支持的情况下定义这种规则的能力,他们能够修改规则,以提高他们的精确度和普适性。
    从动态ePRO数据集学习规则可用于协助人类专家在门诊环境中为癌症患者建立早期预警系统。
    UNASSIGNED: The use of smartphone apps in cancer patients undergoing systemic treatment can promote the early detection of symptoms and therapy side effects and may be supported by machine learning (ML) for timely adaptation of therapies and reduction of adverse events and unplanned admissions.
    UNASSIGNED: We aimed to create an Early Warning System (EWS) to predict situations where supportive interventions become necessary to prevent unplanned visits. For this, dynamically collected standardized electronic patient reported outcome (ePRO) data were analyzed in context with the patient\'s individual journey. Information on well-being, vital parameters, medication, and free text were also considered for establishing a hybrid ML model. The goal was to integrate both the strengths of ML in sifting through large amounts of data and the long-standing experience of human experts. Given the limitations of highly imbalanced datasets (where only very few adverse events are present) and the limitations of humans in overseeing all possible cause of such events, we hypothesize that it should be possible to combine both in order to partially overcome these limitations.
    UNASSIGNED: The prediction of unplanned visits was achieved by employing a white-box ML algorithm (i.e., rule learner), which learned rules from patient data (i.e., ePROs, vital parameters, free text) that were captured via a medical device smartphone app. Those rules indicated situations where patients experienced unplanned visits and, hence, were captured as alert triggers in the EWS. Each rule was evaluated based on a cost matrix, where false negatives (FNs) have higher costs than false positives (FPs, i.e., false alarms). Rules were then ranked according to the costs and priority was given to the least expensive ones. Finally, the rules with higher priority were reviewed by two oncological experts for plausibility check and for extending them with additional conditions. This hybrid approach comprised the application of a sensitive ML algorithm producing several potentially unreliable, but fully human-interpretable and -modifiable rules, which could then be adjusted by human experts.
    UNASSIGNED: From a cohort of 214 patients and more than 16\'000 available data entries, the machine-learned rule set achieved a recall of 19% on the entire dataset and a precision of 5%. We compared this performance to a set of conditions that a human expert had defined to predict adverse events. This \"human baseline\" did not discover any of the adverse events recorded in our dataset, i.e., it came with a recall and precision of 0%. Despite more plentiful results were expected by our machine learning approach, the involved medical experts a) had understood and were able to make sense of the rules and b) felt capable to suggest modification to the rules, some of which could potentially increase their precision. Suggested modifications of rules included e.g., adding or tightening certain conditions to make them less sensitive or changing the rule consequences: sometimes further monitoring the situation, applying certain test (such as a CRP test) or applying some simple pain-relieving measures was deemed sufficient, making a costly consultation with the physician unnecessary. We can thus conclude that it is possible to apply machine learning as an inspirational tool that can help human experts to formulate rules for an EWS. While humans seem to lack the ability to define such rules without such support, they are capable of modifying the rules to increase their precision and generalizability.
    UNASSIGNED: Learning rules from dynamic ePRO datasets may be used to assist human experts in establishing an early warning system for cancer patients in outpatient settings.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:在癌症患者的临床研究中越来越多地使用电子患者报告结果(ePRO)的评估,并能够在患者的日常生活中进行结构化和标准化的数据收集。到目前为止,很少有研究或分析关注ePROs对患者的医疗益处。
    目的:当前的探索性分析旨在初步表明,与不使用真实世界护理应用程序的对照组相比,使用ConsiliumCare应用程序(最近更名为medidux;mobileHealthAG)对ePro的副作用进行结构化和定期自我评估对癌症患者的计划外咨询和住院的发生率具有可识别的影响。为了分析这一点,使用ConsiliumCare应用程序记录的癌症患者的计划外会诊和住院治疗的发生率,作为患者报告结局(PRO)研究的一部分,我们将其与在标准护理治疗期间在瑞士2个肿瘤中心收集的癌症患者的可比人群的相应数据进行回顾性比较.
    方法:PRO研究中接受新辅助或非治疗性全身治疗的癌症患者(本分析中包括178例)通过ConsiliumCare应用程序在90天的观察期内对副作用进行了自我评估。在这个时期,参与医师记录了计划外(紧急)会诊和住院情况.将这些事件的发生率与从瑞士2个肿瘤中心获得的一组癌症患者的回顾性数据进行比较。
    结果:两组患者在年龄和性别比例方面具有可比性,以及癌症实体和癌症分期联合委员会的分布。总的来说,每组139例患者接受化疗,39例接受其他治疗。看着所有的病人,Consilium组和对照组在每位患者的事件中没有发现显著差异(比值比0.742,90%CI0.455~1.206).然而,多元回归模型显示,Consilium组和"化疗"因子之间的相互作用项在5%水平上显著(P=.048).这激发了相应的亚组分析,表明在接受化疗的患者亚组中,干预组的风险相关降低。相应的比值比为0.53,90%CI0.288-0.957相当于Consilium组患者的风险减半,并表明临床相关效应在双侧10%水平上显著(P=.08,Fisher精确检验)。
    结论:PRO研究的计划外会诊和住院情况与来自癌症患者的可比队列的回顾性数据的比较表明,定期使用基于应用程序的ePRO对接受化疗的患者具有积极作用。这些数据将在正在进行的随机PRO2研究(在ClinicalTrials.gov;NCT05425550注册)中得到验证。
    背景:ClinicalTrials.govNCT03578731;https://www.clinicaltrials.gov/ct2/show/NCT03578731.
    RR2-10.2196/29271。
    BACKGROUND: The evaluation of electronic patient-reported outcomes (ePROs) is increasingly being used in clinical studies of patients with cancer and enables structured and standardized data collection in patients\' everyday lives. So far, few studies or analyses have focused on the medical benefit of ePROs for patients.
    OBJECTIVE: The current exploratory analysis aimed to obtain an initial indication of whether the use of the Consilium Care app (recently renamed medidux; mobile Health AG) for structured and regular self-assessment of side effects by ePROs had a recognizable effect on incidences of unplanned consultations and hospitalizations of patients with cancer compared to a control group in a real-world care setting without app use. To analyze this, the incidences of unplanned consultations and hospitalizations of patients with cancer using the Consilium Care app that were recorded by the treating physicians as part of the patient reported outcome (PRO) study were compared retrospectively to corresponding data from a comparable population of patients with cancer collected at 2 Swiss oncology centers during standard-of-care treatment.
    METHODS: Patients with cancer in the PRO study (178 included in this analysis) receiving systemic therapy in a neoadjuvant or noncurative setting performed a self-assessment of side effects via the Consilium Care app over an observational period of 90 days. In this period, unplanned (emergency) consultations and hospitalizations were documented by the participating physicians. The incidence of these events was compared with retrospective data obtained from 2 Swiss tumor centers for a matched cohort of patients with cancer.
    RESULTS: Both patient groups were comparable in terms of age and gender ratio, as well as the distribution of cancer entities and Joint Committee on Cancer stages. In total, 139 patients from each group were treated with chemotherapy and 39 with other therapies. Looking at all patients, no significant difference in events per patient was found between the Consilium group and the control group (odds ratio 0.742, 90% CI 0.455-1.206). However, a multivariate regression model revealed that the interaction term between the Consilium group and the factor \"chemotherapy\" was significant at the 5% level (P=.048). This motivated a corresponding subgroup analysis that indicated a relevant reduction of the risk for the intervention group in the subgroup of patients who underwent chemotherapy. The corresponding odds ratio of 0.53, 90% CI 0.288-0.957 is equivalent to a halving of the risk for patients in the Consilium group and suggests a clinically relevant effect that is significant at a 2-sided 10% level (P=.08, Fisher exact test).
    CONCLUSIONS: A comparison of unplanned consultations and hospitalizations from the PRO study with retrospective data from a comparable cohort of patients with cancer suggests a positive effect of regular app-based ePROs for patients receiving chemotherapy. These data are to be verified in the ongoing randomized PRO2 study (registered on ClinicalTrials.gov; NCT05425550).
    BACKGROUND: ClinicalTrials.gov NCT03578731; https://www.clinicaltrials.gov/ct2/show/NCT03578731.
    UNASSIGNED: RR2-10.2196/29271.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Randomized Controlled Trial
    背景:随着越来越多的患者报告结果(PRO)来测量肿瘤患者的健康相关生活质量(HRQoL),关于如何在患者护理中解释和使用这些数据,目前仍缺乏标准化的策略.先前的研究表明,支持将数字PRO监控与警报系统一起使用,以在PRO值恶化时通知临床医生。该系统已证明在改善HRQoL和提高肿瘤患者的生存率方面具有优势。因此,我们设计了PROB研究,一项优势多中心随机对照试验,研究基于警报的监测对德国转移性乳腺癌患者的影响。PROB研究的研究方案于2021年9月发布,该手稿描述了PROB研究的正式统计分析计划(SAP),以提高该试验的透明度和质量。
    方法:该试验旨在招募1000名转移性乳腺癌患者。然而,截至2023年6月15日,我们已成功纳入来自52个乳腺癌中心的924名患者.患者按1:1分层随机分为干预组和对照组。基于应用程序的PRO问卷每周发送到干预组,每3个月发送到对照组。只有干预组中的患者在PRO评分恶化时触发警报,随后在48小时内与当地护理团队联系。主要结果是6个月时的疲劳评分,次要结局是其他HRQoL和总生存率。将使用线性混合模型对研究中心进行随机拦截,对干预措施的优越性进行评估。
    结论:本详细的SAP定义了PROB研究的统计分析的主要组成部分,以帮助统计学家并防止在选择分析和报告结果时出现偏倚。SAP的版本1于2024年1月18日完成。
    背景:DRKS(德国临床试验注册)DRKS00024015。2021年2月15日注册。
    BACKGROUND: With an increasing collection of patient-reported outcomes (PROs) to measure health-related quality of life (HRQoL) in oncological patients, there is still a lack of standardised strategies on how to interpret and use these data in patient care. Prior research has shown support for the use of digital PRO monitoring together with alarm systems to notify clinicians when the PRO values are deteriorating. This system has demonstrated advantages in improving HRQoL and increasing survival rates among oncology patients. Hence, we designed the PRO B study, a superiority multi-centre randomised controlled trial, to investigate the effects of alarm-based monitoring in metastatic breast cancer patients in Germany. The study protocol for the PRO B study was published in September 2021, and this manuscript describes a formal statistical analysis plan (SAP) for the PRO B study to improve the transparency and quality of this trial.
    METHODS: The trial aimed to recruit 1000 patients with metastatic breast cancer. However, as of the completion of recruitment on June 15, 2023, we have successfully enrolled 924 patients from 52 breast cancer centres. Patients were 1:1 stratified randomised to the intervention and control groups. App-based PRO questionnaires are sent weekly to the intervention group and every 3 months to the control group. Only patients in the intervention group trigger an alarm if their PRO scores deteriorate, and they are subsequently contacted by the local care team within 48 h. The primary outcome is the fatigue score at 6 months, and secondary outcomes are other HRQoL and overall survival. Evaluation of the superiority of the intervention will be done using a linear mixed model with random intercepts for study centres.
    CONCLUSIONS: This detailed SAP defines the main components of the statistical analysis for the PRO B study to assist the statistician and prevent bias in selecting analysis and reporting findings. Version 1 of the SAP was finalised on January 18, 2024.
    BACKGROUND: DRKS (German Clinical Trials Register) DRKS00024015 . Registered on February 15, 2021.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:及时收集患者报告结果(PRO)可减少急诊就诊次数和住院次数,并提高生存率。然而,关于使用类似临床结局评估的无薪非正式护理人员报告的结局预测性知之甚少。
    目的:本研究的目的是评估护理人员和癌症患者是否遵守计划的时间表,以电子方式收集患者报告的结果(PRO),以及PRO是否与未来的临床事件相关。
    方法:我们开发了2个iPhone应用程序来收集PRO,一个是癌症患者,另一个是护理人员。在一项非随机研究中,我们招募了来自北加州KaiserPermanente的52名患者-护理人员。参与者独立使用应用程序4周。在研究后6个月内,从患者的电子健康记录中获得具体的临床事件。我们使用逻辑斯和准泊松回归分析来测试PRO和临床事件之间的关联。
    结果:参与者完成了97%(251/260)的计划患者报告结果不良事件通用术语标准(PRO-CTCAE)调查和98%(254/260)的患者报告结果测量信息系统(PROMIS)调查。护理人员完成的PRO-CTCAE调查与患者住院或急诊就诊相关,3-4级治疗相关不良事件,剂量减少(P<0.05),和临终关怀转诊(P=0.03)。护理人员完成的PROMIS调查与临终关怀转诊相关(P=0.02)。患者完成的PRO-CTCAE调查与任何临床事件无关。但他们的基线PROMIS调查与死亡率相关(P=.03),而他们的前期或最终的PROMIS调查与所检查的所有临床事件相关,但治疗中断的总天数除外.
    结论:在这项研究中,护理人员和患者根据要求使用智能手机应用程序完成了PRO。护理人员PRO-CTCAE调查与患者临床事件的关联表明,这是减少临床试验数据收集中患者负担的可行方法,并且可能有助于提供有关症状严重程度增加的早期信息。
    Timely collection of patient-reported outcomes (PROs) decreases emergency department visits and hospitalizations and increases survival. However, little is known about the outcome predictivity of unpaid informal caregivers\' reporting using similar clinical outcome assessments.
    The aim of this study is to assess whether caregivers and adults with cancer adhered to a planned schedule for electronically collecting patient-reported outcomes (PROs) and if PROs were associated with future clinical events.
    We developed 2 iPhone apps to collect PROs, one for patients with cancer and another for caregivers. We enrolled 52 patient-caregiver dyads from Kaiser Permanente Northern California in a nonrandomized study. Participants used the apps independently for 4 weeks. Specific clinical events were obtained from the patients\' electronic health records up to 6 months following the study. We used logistic and quasi-Poisson regression analyses to test associations between PROs and clinical events.
    Participants completed 97% (251/260) of the planned Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) surveys and 98% (254/260) of the Patient-Reported Outcomes Measurement Information System (PROMIS) surveys. PRO-CTCAE surveys completed by caregivers were associated with patients\' hospitalizations or emergency department visits, grade 3-4 treatment-related adverse events, dose reductions (P<.05), and hospice referrals (P=.03). PROMIS surveys completed by caregivers were associated with hospice referrals (P=.02). PRO-CTCAE surveys completed by patients were not associated with any clinical events, but their baseline PROMIS surveys were associated with mortality (P=.03), while their antecedent or final PROMIS surveys were associated with all clinical events examined except for total days of treatment breaks.
    In this study, caregivers and patients completed PROs using smartphone apps as requested. The association of caregiver PRO-CTCAE surveys with patient clinical events suggests that this is a feasible approach to reducing patient burden in clinical trial data collection and may help provide early information about increasing symptom severity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Editorial
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    通过消除参与者频繁访问研究地点的要求,手机应用程序(“应用程序”)可能有助于分散临床试验。应用程序也可能是捕获患者报告的结果和其他端点的有效机制,帮助在临床试验期间和之外优化患者护理。
    我们报告了数字生物标记对临床影响的可用性(DigiBioMarC™(DBM)),癌症患者与可穿戴设备(AppleWatch®)结合使用的新型基于智能手机的应用程序。DBM旨在收集患者报告的结果并记录身体功能。
    在完全分散的“自带设备”智能手机研究中,从2020年10月至2021年3月,我们纳入了来自北加州KaiserPermanente(KPNC)的54名癌症患者和护理人员.患者使用该应用程序至少28天,每周完成关于他们症状的问卷,物理功能,和心情,并执行定时物理任务。可用性是通过移动应用程序评级量表(MARS)的一个子集来确定的,完整的系统可用性量表(SUS),净启动子得分(NPS),半结构化面试。
    我们从54名患者中的50名获得了可用性调查数据。对所选MARS问题的中间回答和平均SUS分数表明高于平均可用性。研究结束时,半结构化访谈的NPS为24,表明得分良好。
    癌症患者报告的DBM应用程序可用性高于平均水平。定性分析表明,该应用程序易于使用且很有用。未来的工作将强调实施进一步的患者建议和评估应用程序的临床疗效在多个设置。
    UNASSIGNED: By eliminating the requirement for participants to make frequent visits to research sites, mobile phone applications (\"apps\") may help to decentralize clinical trials. Apps may also be an effective mechanism for capturing patient-reported outcomes and other endpoints, helping to optimize patient care during and outside of clinical trials.
    UNASSIGNED: We report on the usability of Digital BioMarkers for Clinical Impact (DigiBioMarC™ (DBM)), a novel smartphone-based app used by cancer patients in conjunction with a wearable device (Apple Watch®). DBM is designed to collect patient-reported outcomes and record physical functions.
    UNASSIGNED: In a fully decentralized \"bring-your-own-device\" smartphone study, we enrolled 54 cancer patient and caregiver dyads from Kaiser Permanente Northern California (KPNC) from October 2020 through March 2021. Patients used the app for at least 28 days, completed weekly questionnaires about their symptoms, physical functions, and mood, and performed timed physical tasks. Usability was determined through a subset of the Mobile App Rating Scale (MARS), the full System Usability Scale (SUS), the Net Promoter Score (NPS), and semi-structured interviews.
    UNASSIGNED: We obtained usability survey data from 50 of 54 patients. Median responses to the selected MARS questions and the mean SUS scores indicated above average usability. The NPS from the semi-structured interviews at the end of the study was 24, indicating a favorable score.
    UNASSIGNED: Cancer patients reported above average usability for the DBM app. Qualitative analyses indicated that the app was easy to use and helpful. Future work will emphasize implementing further patient recommendations and evaluating the app\'s clinical efficacy in multiple settings.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    Patient-reported outcomes (PROs) are an emerging paradigm in clinical research and healthcare, aiming to capture the patient\'s self-assessed health status in order to gauge efficacy of treatment from their perspective. As these patient-generated health data provide insights into the effects of healthcare processes in real-life settings beyond the clinical setting, they can also be viewed as a resolution beyond what can be gleaned directly by the clinician. To this end, patients are identified as a key stakeholder of the healthcare decision making process, instead of passively following their doctor\'s guidance. As this joint decision-making process requires constant and high-quality communication between the patient and his/her healthcare providers, novel methodologies and tools have been proposed to promote richer and preemptive communication to facilitate earlier recognition of potential complications. To this end, as PROs can be used to quantify the patient impact (especially important for chronic conditions such as cancer), they can play a prominent role in providing patient-centric care. In this paper, we introduce the MyPal platform that aims to support adults suffering from hematologic malignancies, focusing on the technical design and highlighting the respective challenges. MyPal is a Horizon 2020 European project aiming to support palliative care for cancer patients via the electronic PROs (ePROs) paradigm, building upon modern eHealth technologies. To this end, MyPal project evaluate the proposed eHealth intervention via clinical studies and assess its potential impact on the provided palliative care. More specifically, MyPal platform provides specialized applications supporting the regular answering of well-defined and standardized questionnaires, spontaneous symptoms reporting, educational material provision, notifications etc. The presented platform has been validated by end-users and is currently in the phase of pilot testing in a clinical study to evaluate its feasibility and its potential impact on the quality of life of palliative care patients with hematologic malignancies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Clinical Trial Protocol
    BACKGROUND: Despite the progress of research and treatment for breast cancer, still up to 30% of the patients afflicted will develop distant disease. Elongation of survival and maintaining the quality of life (QoL) become pivotal issues guiding the treatment decisions. One possible approach to optimise survival and QoL is the use of patient-reported outcomes (PROs) to timely identify acute disease-related burden. We present the protocol of a trial that investigates the effect of real-time PRO data captured with electronic mobile devices on QoL in female breast cancer patients with metastatic disease.
    METHODS: This study is a randomised, controlled trial with 1:1 randomisation between two arms. A total of 1000 patients will be recruited in 40 selected breast cancer centres. Patients in the intervention arm receive a weekly request via an app to complete the PRO survey. Symptoms will be assessed by study-specific optimised short forms based on the EORTC QLQ-C30 domains using items from the EORTC CAT item banks. In case of deteriorating PRO scores, an alarm is sent to the treating study centre as well as to the PRO B study office. Following the alarm, the treating breast cancer centre is required to contact the patient to inquire about the reported symptoms and to intervene, if necessary. The intervention is not specified and depends on the clinical need determined by the treating physician. Patients in the control arm are prompted by the app every 3 months to participate in the PRO survey, but their response will not trigger an alarm. The primary outcome is the fatigue level 6 months after enrolment. Secondary endpoints include among others hospitalisations, use of rescue services and overall QoL.
    CONCLUSIONS: Within the PRO B intervention group, we expect lower fatigue levels 6 months after intervention start, higher levels of QoL, less unplanned hospitalisations and less emergency room visits compared to controls. In case of positive results, our approach would allow a fast and easy transfer into clinical practice due to the use of the already nationwide existing IT infrastructure of the German Cancer Society and the independent certification institute OnkoZert.
    BACKGROUND: DRKS (German Clinical Trials Register) DRKS00024015 . Registered on 15 February 2021.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    患者的生活质量及其评估仍然是肿瘤学的首要目标之一。已经开发了不同的生活质量评估方法和工具,目的是进行全球评估,在不同的方面,无论是身体上的,情感,心理或社会。生活质量问卷改善并简化了临床试验期间患者的重新评估和随访。患者报告的结果测量(PROMs)是对患者所经历的生活质量的评估(患者报告的结果[PROs]),并允许医生采用个性化的治疗方法。在放射治疗中,PROM是治疗期间或治疗后患者随访的有用工具。技术的进步,特别是在数据收集方面,而且在他们的整合和治疗方面,人工智能将允许将这些评估工具整合到肿瘤学患者的管理中。
    The quality of life of patients and its evaluation remains one of the primordial objectives in oncology. Different methods and tools of evaluation of quality of life have been developed with the objective of having a global evaluation, throughout different aspects, be it physical, emotional, psychological or social. The quality of life questionnaires improve and simplify the reevaluation and follow-up of patients during clinical trials. Patient reported outcome measures (PROMs) are an evaluation of the quality of life as experienced by the patients (patient-reported-outcomes [PROs]) and allow for physicians a personalized treatment approach. In radiotherapy, PROMs are a useful tool for the follow-up of patients during or after treatment. The technological advances, notably in data collecting, but also in their integration and treatment with regard to artificial intelligence will allow integrating these evaluation tools in the management of patients in oncology.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    越来越感兴趣和相关性的远程医疗应用是使用个人计算机和移动设备来收集患者报告的结果(PRO)。PROs是患者健康状况的自我报告,没有其他人的解释。为评估PRO而开发的工具被称为患者报告结果测量(PROMs)。导致电子设备所有权增加的技术创新也促进了电子PROM(ePROM)的发展。ePROM是远程医疗在慢性病患者护理中的管道。各种研究已经证明,在常规临床实践中使用ePR0M既是可接受的又是可行的,患者越来越多地表达对电子给药模式的偏好。越来越多的证据表明,使用电子患者报告结果(ePROM)可能会对患者评估的结果产生重大影响。医疗保健提供者和研究人员。虽然这些系统的开发和实施最初可能成本高昂且资源密集,患者的偏好和支持其实施的现有证据表明,需要在该领域继续优先进行研究.这篇叙述性综述总结并讨论了ePROMs对与慢性疾病相关的临床参数和结果的影响的证据。我们还探讨了最近发表的有关可能影响ePROM在常规临床实践中的稳健实施的问题的文献。
    An application of telemedicine of growing interest and relevance is the use of personal computers and mobile devices to collect patient-reported outcomes (PROs). PROs are self-reports of patients\' health status without interpretation by anyone else. The tools developed to assess PROs are known as patient-reported outcomes measures (PROMs). The technological innovations that have led to an increased ownership of electronic devices have also facilitated the development of electronic PROMs (ePROMs). ePROMs are a conduit for telemedicine in the care of patients with chronic diseases. Various studies have demonstrated that the use of ePROMs in routine clinical practice is both acceptable and feasible with patients increasingly expressing a preference for an electronic mode of administration. There is increasing evidence that the use of electronic patient-reported outcome (ePROMs) could have significant impacts on outcomes valued by patients, healthcare providers and researchers. Whilst the development and implementation of these systems may be initially costly and resource-intensive, patient preferences and existing evidence to support their implementation suggests the need for continued research prioritisation in this area. This narrative review summarises and discusses evidence of the impact of ePROMs on clinical parameters and outcomes relevant to chronic diseases. We also explore recently published literature regarding issues that may influence the robust implementation of ePROMs for routine clinical practice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号